Back to Results
First PageMeta Content
Proteins / CDK inhibitor / Ki-67 / Cyclin-dependent kinase / Cyclin / Biology / Cell biology / Cell cycle


Identification of a Predicted Biologically Effective Dose of AT7519, a Cyclin Dependent Kinase Inhibitor, in a Phase I Study[removed]M. S. Squires1, V. Lock1, J. Adam2 , D. Smith1, N. T. Thompson1, M. Yule1, J. F. Lyons1,
Add to Reading List

Document Date: 2012-12-13 18:06:00

Open Document

File Size: 207,13 KB

Share Result on Facebook

City

Denver / Newcastle upon Tyne / Tucson / Cambridge / /

Company

PHARMACODYNAMICS Normalised Ki67 IHC INTRODUCTION Therapeutics Ltd. / Time (h) Co / Astex Therapeutics Limited. / /

Country

United Kingdom / /

Currency

pence / /

Facility

Cancer Center / /

IndustryTerm

active site / Cancer Treatment / /

MedicalCondition

retinoblastoma protein / refractory solid tumours / patient experienced bronchospasm / tumour / CDK2 Colon Carcinoma / HT29 Ovarian Carcinoma / Hypotension / Tumours / /

MedicalTreatment

intravenous infusion / /

Organization

2The Northern Centre for Cancer Treatment / 3Arizona Cancer Center / /

Technology

PHARMACOKINETICS / apoptosis / /

URL

www.astex-therapeutics.com / /

SocialTag